11 CHEMICALS KNOWLEDGE HUB Issue 2 / October 2025 Sunresin New Materials Co., Ltd. has announced plans to invest USD 160 million in the construction of a HighEnd Life Science Advanced Materials Industrial Park in the Pucheng High-Tech Industrial Development Zone, China. The project will span approximately 18 hectares and serve as a flagship facility for the development and large-scale production of critical bioprocessing materials, including: - Agarose and polymeric chromatography media - Enzyme carriers - Resins for oligonucleotide and peptide solid phase synthesis - Adsorption resins and separation materials - GMP facility for manufacturing APIs and excipients - Resins for ultrapure water production - Food- and biopharma-grade resins - Chromatographic equipment This investment highlights Sunresin’s strategy to grow its life sciences business, meet the increasing global demand for downstream processing solutions, and solidify its standing as a leading innovator in the field. “The creation of this new industrial park reflects Sunresin’s confidence in the long-term growth of the life sciences sector,” said Dr. Ivy Gao, CEO of Sunresin. “By expanding our capacity and capabilities, including a new GMP facility for the manufacturing of APIs and excipients, we aim to provide the global biopharmaceutical industry with more reliable, high-performance chromatography resins and separation technologies.” Although the initiative may not affect financial performance immediately, it positions Sunresin to take advantage of emerging opportunities in biopharmaceuticals, advanced therapies, and global downstream processing. According to the company, land acquisition will take place through a public auction, and construction and development are subject to the usual regulatory approvals. NEWS Sunresin announces USD 160 million investment to build state-of-the-art life sciences industrial park in Pucheng and transparency, and I look forward to being part of developing new next generation therapies”. She added, “I am ambitious in my expectations of how my global operational experience can positively impact Symeres’ growth targets and I’m committed to delivering outstanding customer experiences. Symeres’ growth trajectory makes this an exciting time to join.” Guillaume Jetten, Symeres CEO, added “I’m delighted that Gabriella has accepted this position. ‘Gabriella brings a set of highly relevant skills and experience from both her background in medicinal chemistry, but also her decades of large Pharma and biotech experience that will support the future growth plans of Symeres”. Most recently, Gabriella served as global improvement director at Catalent, where she developed and implemented standardized operational frameworks across multiple sites. Prior to that, she consulted independently on global change and operational excellence programs, helping organizations improve performance and implement strategic business initiatives. Her appointment marks another significant step in Symeres’ expansion strategy, as the company positions itself as a global biotechnology leader bridging European innovation and American market presence.
RkJQdWJsaXNoZXIy MjY2OTA4MA==